» Articles » PMID: 20427358

Cancer Incidence and Mortality in Spain: Estimates and Projections for the Period 1981-2012

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2010 Apr 30
PMID 20427358
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: National indicators of cancer burden are essential information for cancer surveillance and health planning, so that in countries with partial registration coverage and geographically variable risk patterns, such as Spain, this is even more relevant. This article provides estimates of cancer incidence in Spain for all cancers combined, with the single exception of non-melanoma skin cancer, and for major cancer sites over the period 1981-2006, with projections up to 2012.

Patients And Methods: Estimates were obtained by applying the MIAMOD method, a statistical back-calculation approach, to derive incidence from mortality and relative survival data.

Results: During the period 1981-2012, age-standardised incidence rates for all cancers rose from the beginning of the period and started to decline from 2000 onwards among men, and increased across the whole period among women. Differences in incidence trends between men and women might be attributable to the gender-specific case-mix of sites for all cancers, and to differences in risk factors specific to certain cancer sites in men and women, with smoking being the main factor accounting for these differences between the sexes.

Conclusions: Estimates and projections of cancer incidence and mortality show divergent trends in Spain by sex and tumour type. This information is basic for planning and enhancing public health strategies and resources.

Citing Articles

[Evolution of the incidence and survival of bronchogenic carcinoma in the province of Castellón (Spain) from 2004 to 2017.].

Miravet Sorribes L, Montoliu Nebot J, Iradi Casal A, Carrera Hueso F, Arnedo Pena A Rev Esp Salud Publica. 2023; 97.

PMID: 37325902 PMC: 10558110.


Exploring Cancer Incidence, Risk Factors, and Mortality in the Lleida Region: Interactive, Open-source R Shiny Application for Cancer Data Analysis.

Florensa D, Mateo-Fornes J, Lopez Sorribes S, Torres Tuca A, Solsona F, Godoy P JMIR Cancer. 2023; 9:e44695.

PMID: 37079353 PMC: 10160936. DOI: 10.2196/44695.


Survival Benefits for Pulmonary Adenocarcinoma With Malignant Pleural Effusion After Thoracoscopic Surgical Treatment: A Real-World Study.

Li X, Li M, Lv J, Liu J, Dong M, Xia C Front Oncol. 2022; 12:843220.

PMID: 35600389 PMC: 9117620. DOI: 10.3389/fonc.2022.843220.


Statistical projection methods for lung cancer incidence and mortality: a systematic review.

Yu X, Luo Q, Hughes S, Wade S, Caruana M, Canfell K BMJ Open. 2019; 9(8):e028497.

PMID: 31462469 PMC: 6720154. DOI: 10.1136/bmjopen-2018-028497.


Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain.

Galve-Calvo E, Gonzalez-Haba E, Gostkorzewicz J, Martinez I, Perez-Mitru A Clinicoecon Outcomes Res. 2018; 10:773-790.

PMID: 30532569 PMC: 6241542. DOI: 10.2147/CEOR.S178934.